HPV-vaccination for the prevention of cervical cancer in Austria: A model based long-term prognosis of cancer epidemiology

Journal of Public Health

Volumn 18, Issue 1, 2010, Pages 3-13

  Zechmeister, Ingrid ^a   Freiesleben De Blasio, Birgitte ^b   Garnett, Geoff ^c  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^b UNIVERSITY OF OSLO   (Norway)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Austria; Cervical carcinoma incidence; Cervical carcinoma mortality; HPV vaccination

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; ATTITUDE TO SEXUALITY; AUSTRIA; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CHILD; DISEASE COURSE; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MODEL; SEXUAL BEHAVIOR; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; VACCINATION; VALIDATION STUDY; VIRUS TRANSMISSION; WART VIRUS;

EID: 74349109469     PISSN: 09431853     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10389-009-0276-3     Document Type: Article

References (38)

1. Barnabas RV, Garnett GP (2005) The potential public health impact of vaccines against human papillomavirus. In: Prendiville W, Davies P (eds) The health professionals HPV handbook. Taylor & Francis, Abingdon
2. C Bergeron N Largeron R McAllister P Mathevet V Remy 2008 Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France International Journal of Health Technology Assessment in Health Care 24 10 19 (Pubitemid 351158538)
3. M Brisson N Van der Velde P De Wals M-C Boily 2007 The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada Vaccine 25 5399 5408 10.1016/j.vaccine.2007.04.086 17561316 (Pubitemid 46977529)
4. Bundesministerium für Gesundheit Familie und Jugend (BMGFJ) (2007) Impfstatistik. In. Bundesministerium für Gesundheit, Familie und Jugend; Abteilung Infektionskrankheiten, Seuchenbekämpfung und Krisenmanagement, Wien
5. J Coste B Cochand-Priollet P de Cremoux C Le Galés I Cartier V Molinié S Labbé M-C Vacher-Lavenu P Vielh 2003 Cross sectional study of conventional cervical smear, monolayer cytology, and human papillomavirus DNA testing for cervical cancer screening Br Med J 326 733 10.1136/bmj.326.7392.733
6. EJ Dasbach R Insinga EH Elbahsa 2008 The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. BJOG An International Journal of Obstetrics and Gynaecology 115 947 956 10.1111/j.1471-0528.2008.01743.x 1:STN:280:DC%2BD1cvntVyntw%3D%3D (Pubitemid 351841762)
7. EH Elbasha EJ Dasbach RP Insinga 2007 Model for assessing human papillomavirus vaccination strategies Emerg Infect Dis 13 28 41 10.3201/eid1301.060438 17370513
8. Ferlay J, Bray F, Pisani P, Parkin DM (2004) GLOBCAN 2002 cancer incidence. mortality and prevalence worldwide. In: IARC CancerBase No. 5 version 2.0. IARC Press, Lyon
9. KM French RV Barnabas M Lehtinen O Kontula E Pukkala J Dillner GP Garnett 2007 Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland Br J Cancer 96 514 518 10.1038/sj.bjc.6603575 1:STN:280:DC%2BD2s%2Fos1WmsA%3D%3D 17245341 (Pubitemid 46215226)
10. GP Garnett 2005 Role of herd immunity in determining the effect of vaccines against sexually transmitted disease J Infect Dis 191 s97 s106 10.1086/425271 15627236 (Pubitemid 40144234)
11. GP Garnett JJ Kim K French SJ Goldie 2006 Modelling the impact of HPV vaccines on cervical cancer and screening programmes Vaccine 24S3 178 186 10.1016/j.vaccine.2006.05.116 (Pubitemid 44293028)
12. SJ Goldie M Kohli D Grima MC Weinstein TC Wright FX Bosch E Franco 2004 Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine J Natl Cancer Inst 96 604 615 15100338
13. SJ Goldie JJ Kim K Kobus JD Goldhaber-Fiebert J Salomon MKH O'Shea X Bosch S de Sanjosé E Franco 2007 Cost-effectiveness of HPV 16, 18 vaccination in Brazil Vaccine 25 6257 6270 10.1016/j.vaccine.2007.05.058 17606315 (Pubitemid 47088030)
14. Hackl M (2007) Krebsstatistik. Sonderauswertung. In: Statistik Austria, Wien
15. Hauptverband der österreichischen Sozialversicherungsträger (2007) Datenerhebung Pap-Abstrich. In: Hauptverband der österreichischen Sozialversicherungsträger, Wien
16. GY Ho R Bierman L Beardsley CJ Chang RD Burk 1998 Natural history of cervicovaginal papillomavirus infection among cytologically normal women N Eng J Med 338 423 428 10.1056/NEJM199802123380703 1:STN:280:DyaK1c7hslSluw%3D%3D (Pubitemid 28135669)
17. JP Hughes GP Garnett LA Koutsky 2002 The theoretical population-level impact of a phrophylactic human papilloma virus vaccine Epidemiology 13 631 639 10.1097/00001648-200211000-00006 12410003 (Pubitemid 44698466)
18. R Insinga EJ Dasbach EH Elbahsa A Puig LM Reynales-Shigematsu 2007 Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation Vaccine 26 128 139 10.1016/j.vaccine.2007.10.056 18055075 (Pubitemid 350218187)
19. M Jit YH Choi WJ Edmunds 2008 Economic evaluation of human papillomavirus vaccination in the United Kingdom Br Med J 337 a769 10.1136/bmj.a769
20. J Kim S Goldie 2008 Health and economic implications of HPV vaccination in the United States N Eng J Med 359 821 832 10.1056/NEJMsa0707052 1:CAS:528:DC%2BD1cXhtVShur3L
21. JJ Kim KM Kuntz NK Stout S Mahmud LL Villa E Franco S Goldie 2007 Multiparameter calibration of a natural history model of cervical cancer Am J Epidemiol 166 137 150 10.1093/aje/kwm086 17526866 (Pubitemid 47227293)
22. M Kohli N Ferko A Martin E Franco D Jenkins S Gallivan C Sherlaw-Johnson M Drummond 2007 Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK Br J Cancer 96 143 150 10.1038/sj.bjc.6603501 1:STN:280:DC%2BD2s%2Fhs1Oiuw%3D%3D 17146475 (Pubitemid 46094653)
23. SL Kulasingam ER Myers 2003 Potential health and economic impact of adding a human papillomavirus vaccine to screening programs J Am Med Assoc 290 781 789 10.1001/jama.290.6.781 (Pubitemid 37432955)
24. SL Kulasingam S Benard RV Barnabas N Largeron ER Myers 2008 Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: a cost-effectiveness analysis Cost Effectiveness and Resource Allocation 6 4 10.1186/1478-7547-6-4 18279515
25. N Muñoz F Bosch X Castellasague M Díaz S de Sanjose D Hammouda K Shah C Meijer 2004 Against which human paillomavirus types shall we vaccinate and screen? Int J Cancer 111 278 285 10.1002/ijc.20244 15197783 (Pubitemid 38924707)
26. N Muñoz F Mendez H Posso M Molano AJ van den Brule M Ronderos C Meijer A Munoz 2004 Incidence, duration, and determination of cervical human papillomavirus infection in a cohort of Columbian women with normal cytological results J Infect Dis 190 2077 2087 10.1086/425907 15551205 (Pubitemid 39636354)
27. National Board of Health, Danish Centre for Health Technology Assessement (2007) Reduction in the risk of cervical cancer by vaccination against human papillomavirus (HPV) - a health technology assessment. In: National Board of Health, Danish Centre for Health Technology Assessment, Copenhagen
28. Neilson A, Freiesleben de Blasio B (2007) Economic evaluation of the human papillomavirus (HPV)-vaccination in Norway. In: Norwegian Knowledge Centre for the Health Services, Oslo
29. Nielsen E, Alfsen GC, Feiring B, Skjeldestad FE, Steen R, Saeterdal I (2007) Prophylactic vaccines against human papillomavirus. In: Norwegian Knowledge Centre for the Health Services, Oslo
30. Piso B, Wild C (2008) Rational vaccination policy - decision support. Review of international literature for 'rational' vaccination policies. In: Ludwig Boltzmann Institute for Health Technology Assessment, Wien
31. C Roberts A Tadesse J Sands T Halvorsen T Schonfield A Dalen F Skjeldestad K Jansen 2006 Detection of HPV in Norwegian cervical biopsy specimens with type-specific PCR and reverse line blot assays Clinical Virology 36 277 282 10.1016/j.jcv.2006.03.013 1:CAS:528:DC%2BD28XntlGiu7o%3D (Pubitemid 44088487)
32. G Sanders AV Taira 2003 Cost effectiveness of a potential vaccine for human papillomavirus Emerg Infect Dis 9 37 48 12533280
33. Statistik Austria (2007a) Bevölkerungsstatistik. Einzelauswertung. In: Statistik Austria, Wien
34. Statistik Austria (2007b) Jahrbuch der Gesundheitsstatistik 2005. In: Statistik Austria, Wien
35. AV Taira CP Neukermans GD Sanders 2004 Evaluating human papillomavirus vaccination programs Emerg Infect Dis 10 1915 1923 15550200
36. Thiry N, Lambert M-L, Cleemput I, Huybrechts M, Neyt M, Hulstaert F, De Laet C (2007) HPV vaccination for the prevention of cervical cancer in Belgium: health technology assessment. In: Belgian Health Care Knowledge Centre (KCE), Brussels
37. C Vutuc G Haidinger T Waldhoer F Ahmad G Breitenecker 1999 Prevalence of self-reported cervical cancer screening and impact on cervical cancer mortality in Austria Wien Klin Wochenschr 111 354 359 1:STN:280:DyaK1Mzjs1egtg%3D%3D 10407996
38. I Zechmeister B Freiesleben de Blasio P Radlberger C Wild E Kvas G Garnett A Neilson U Siebert 2009 Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria Vaccine 27 5133 5141 10.1016/j.vaccine.2009.06.039 19567244